

**Hemogenyx Pharmaceuticals Plc**  
("Hemogenyx" or the "Company")

**Collaboration with major US biotechnology company**

*Collaboration to further develop humanized mice as a tool for drug development and testing*

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it has entered into a collaboration with major US biotechnology company in a deal worth up to approximately \$250,000 for Hemogenyx.

The collaboration follows on from the announcement made by the Company on 26 February 2018, which confirmed the filing of a provisional patent application relating to the Company's development of a new type of humanized mice with a chimeric mouse-human blood system. These new humanized mice can be used for disease modelling and drug development.

This application of Hemogenyx's humanized mice as a tool for drug development and testing forms the basis of the Company's collaboration with the US biotech company. The collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the company, and has the potential to generate further income as the collaboration develops.

**Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented:** *"We are pleased to collaborate with a major US biotechnology company, a leader in the field of blood cancer treatment. As we mentioned in our previous announcement, our new type of humanized mice let us extend our work into other disease models and specific drug development. The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate."*

**Enquiries:**

**Hemogenyx Pharmaceuticals Limited**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder  
Dr Robin Campbell, Chairman

[www.hemogenyx.com](http://www.hemogenyx.com)

*Via Walbrook PR*

**Optiva Securities Ltd**

Christian Dennis

Tel: +44 (0)20 3137 1902

**Shard Capital Partners LLP**

Damon Heath, Erik Woolgar

Tel: +44 (0)20 7186 9950

**Peterhouse Corporate Finance Limited**

Lucy Williams, Duncan Vasey

Tel: +44 (0)20 7469 0930

**Walbrook PR**

Paul McManus

Tel: +44 (0)20 7933 8780 or [hemogenyx@walbrookpr.com](mailto:hemogenyx@walbrookpr.com)

Mob: +44 (0)7980 541 893

**About Hemogenyx Pharmaceuticals Plc**

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning -the CDX bi-specific antibody- and a cell therapy product for BM/HSC transplantation the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit [www.hemogenyx.com](http://www.hemogenyx.com).

This information is provided by RNS  
The company news service from the London Stock Exchange

END

MSCEAADAFFKPEAF